Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Merck Ord Shs MKGAF

Alternate Symbol(s): MKKGY

Healthcare

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical... see more

Add To Watchlist

Recent & Breaking News (OTCPK:MKGAF)

Investigational Cladribine Tablets Data Show Greater Treatment Effect in Relapsing MS Patients at a Higher Risk of Disease Progression

PR Newswire April 28, 2017

Merck to Present Rebif® (interferon beta-1a) and Investigational Cladribine Tablets Data at AAN 2017

PR Newswire Europe Non Regulatory April 21, 2017

New Merck Technology Aims to Further Optimize Embryo Incubation and Assessment

PR Newswire Europe Non Regulatory March 10, 2017

NICE Expands Positive Recommendation for Erbitux as First-line Treatment for RAS Wild-type mCRC

PR Newswire Europe Non Regulatory March 2, 2017

Merck Receives Positive CHMP Opinion for New Pergoveris® Fertility Pen

PR Newswire Europe Non Regulatory February 24, 2017

Cladribine Tablets Significantly Reduced Brain Atrophy in Patients With Multiple Sclerosis

PR Newswire Europe Non Regulatory February 9, 2017

Merck and Genea Open Centre of Excellence for Fertility

PR Newswire Europe Non Regulatory January 20, 2017

Merck's Consumer Health Business Drives Consumer-Centric, Purposeful Innovation

PR Newswire Europe Non Regulatory December 6, 2016

FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review

PR Newswire November 29, 2016

With an Extended Fertility Technologies Portfolio Merck Now Covers All IVF Steps

PR Newswire Asia November 17, 2016

Merck KGaA, Darmstadt, Germany's Phase IIb ADDRESS II Results Confirm Potential of Atacicept as a Candidate Therapy for SLE

PR Newswire November 14, 2016

Merck KGaA, Darmstadt, Germany, Presents Phase II Data on the Safety and Efficacy of Atacicept at the 2016 ACR/ARHP Annual Meeting

PR Newswire November 2, 2016

Merck Partners with American Cancer Society to Address Cancer in Women

PR Newswire Europe Non Regulatory November 1, 2016

Merck KGaA, Darmstadt, Germany Partners with American Cancer Society to Address Cancer in Women

PR Newswire November 1, 2016

European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

PR Newswire October 31, 2016

CHMP Adopts Positive Opinion of Metformin, Including Merck's Type 2 Diabetes Treatment Portfolio, in Patients with Renal Impairment

PR Newswire Europe Non Regulatory October 14, 2016

Merck Publishes First International Curiosity Study

PR Newswire Europe Non Regulatory October 12, 2016

Merck KGaA, Darmstadt, Germany, Announces Recipients of Third Annual €1 Million 'Grant for Oncology Innovation' Award

PR Newswire October 10, 2016

Merck KGaA, Darmstadt, Germany, Announces Recipients of Third Annual €1 Million 'Grant for Oncology Innovation' Award

PR Newswire Europe Non Regulatory October 10, 2016

Merck Announces Recipients of Third Annual €1 Million 'Grant for Oncology Innovation' Award

PR Newswire October 10, 2016